

# Program at a glance

## <The 11th Chronic Kidney Disease Frontier Meeting>

February 20 (Sun), 2022	
13:00	<p>13:00-13:05 <b>Opening Remarks</b></p> <p>13:05-13:53 <b>Oral Presentations</b> <b>&lt; Basic 1 &gt;</b> Chairs: Takaaki Abe, Hirokazu Okada O-1 ~ 4</p>
14:00	<p>13:55-14:25 <b>Sponsored Seminar 1</b> Sponsored by Chugai Pharmaceutical Co.,Ltd. Chair: Motoko Yanagita    Speaker: Naoki Nakagawa</p>
15:00	<p>14:35-15:25 <b>Oral Presentations</b> <b>&lt; Basic 2 &gt;</b> Chairs: Masafumi Fukagawa, Ichiei Narita O-5 ~ 8</p> <p>15:25-15:55 <b>Sponsored Seminar 2</b> Sponsored by Sumitomo Dainippon Pharma Co.,Ltd. Chair: Takashi Wada    Speaker: Akira Mima</p>
16:00	<p>16:05-17:05 <b>Oral Presentations</b> <b>&lt; Clinical &gt;</b> Chairs: Kunihiro Yamagata, Hitoshi Sugiyama O-9 ~ 13</p> <p>17:05-17:45 <b>Sponsored Seminar 3</b> Sponsored by Ono Pharmaceutical Co., Ltd. / AstraZeneca K.K. Chair: Naoki Kashihara    Speaker: Kei Fukami</p>
18:00	<p>17:55-18:40 <b>Controversy in the Treatment of Glomerulonephritis</b> Chairs: Masaomi Nangaku, Yon Su Kim Panelists: Li Zuo, Kearnat Praditpornsilpa, Chi-Chih Hung</p>
19:00	<p>18:40-19:25 <b>Invited Lecture</b> <b>Treatment of ANCA-Associated Vasculitis</b> Chair: Shoichi Maruyama Speaker: David Jayne</p> <p>19:25- <b>Closing Remarks</b></p>

13:05–13:53 **Oral Presentations**

**“Basic1”**

Chairs : Takaaki Abe (*Tohoku University School of Medical Sciences/Medicine, Japan*)

Hirokazu Okada (*Department of Nephrology, Saitama Medical University, Japan*)

**O-1 DZNEP, A HISTONE MODIFICATION INHIBITOR, SUPPRESSES RENAL FIBROSIS BY INHIBITING HIF1 A BINDING TO TIMP2 GENE THROUGH REDUCING OPEN CHROMATIN AREA**

Tomotaka Yamazaki, Imari Mimura, Tetsuhiro Tanaka, Masaomi Nangaku  
*Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Japan*

**O-2 Advanced tertiary lymphoid tissues in protocol biopsies are associated with progressive graft dysfunction in kidney transplant recipients**

Yu Ho Lee<sup>1,2</sup>, Yuki Sato<sup>1,3</sup>, Mitsuru Saito<sup>4</sup>, Shingo Fukuma<sup>5</sup>, Masaya Saito<sup>6</sup>,  
Shigenori Yamamoto<sup>1,3</sup>, Atsushi Komatsuda<sup>6</sup>, Nobuhiro Fujiyama<sup>7</sup>, Shigeru Satoh<sup>7</sup>,  
Sang-Ho Lee<sup>8</sup>, Peter Boor<sup>9,10,11</sup>, Tomonori Habuchi<sup>4</sup>, Jürgen Floege<sup>10</sup>,  
Motoko Yanagita<sup>1,12</sup>

<sup>1</sup>*Department of Nephrology, Graduate School of Medicine, Kyoto University, Japan,*

<sup>2</sup>*Division of Nephrology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Republic of Korea,*

<sup>3</sup>*Medical Innovation Center TMK Project, Kyoto University, Japan,*

<sup>4</sup>*Department of Urology, Graduate School of Medicine, Akita University, Japan,*

<sup>5</sup>*Human Health Sciences, Graduate School of Medicine, Kyoto University, Japan,*

<sup>6</sup>*Department of Hematology, Nephrology, and Rheumatology, Graduate School of Medicine, Akita University, Japan,*

<sup>7</sup>*Center for Kidney Disease and Transplantation, Akita University Hospital, Japan,*

<sup>8</sup>*Division of Nephrology, Department of Internal Medicine, Kyung Hee University, Republic of Korea,*

<sup>9</sup>*Institute of Pathology, RWTH University of Aachen, Germany,*

<sup>10</sup>*Division of Nephrology, RWTH University of Aachen, Germany,*

<sup>11</sup>*Electron Microscopy Facility, RWTH University of Aachen, Germany,*

<sup>12</sup>*Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Japan*

**O-3 Profile of circulating microRNAs associated with hyperglycemia and their effect on kidney function decline in patients with type 2 diabetes**

Hiroki Kobayashi<sup>1,2</sup>, Eiichiro Satake<sup>2</sup>, Zaipul I. Md. Dom<sup>2</sup>, Masanori Abe<sup>1</sup>,  
Andrzej S. Krolewski<sup>2</sup>

<sup>1</sup>*Division of Nephrology, Hypertension and Endocrinology, Nihon University School of Medicine, Japan,*

<sup>2</sup>*Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA*

**O-4 Effects of sodium–glucose cotransporter 2 inhibitor, canagliflozin, on glomerular hyperfiltration and oxidative stress in mice with type 2 diabetes**

Megumi Kondo, Kengo Kidokoro, Hiroyuki Kadoya, Yoshihisa Wada,  
Hajime Nagasu, Tamaki Sasaki, Naoki Kashihara  
*Kawasaki Medical School, Japan*

**13:55-14:25 Sponsored Seminar 1**

Sponsored by Chugai Pharmaceutical Co.,Ltd.

Chair : Motoko Yanagita (*Department of Nephrology, Graduate School of Medicine, Kyoto University, Japan*)

**SS-1 Update on the treatment of refractory nephrotic syndrome**

Naoki Nakagawa

*Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan*

**14:35-15:25 Oral Presentations**

**“Basic2”**

Chairs : Masafumi Fukagawa (*Division of Nephrology, Endocrinology and Metabolism Tokai University School of Medicine, Japan*)

Ichiei Narita (*Division of Clinical Nephrology and Rheumatology, Kidney Research Center, Niigata University, Japan*)

**O-5 Nicotinic acetylcholine receptor agonist reduces acute lung injury after renal ischemia-reperfusion injury by acting on splenic macrophages in mice**

Daiki Goto, Soichiro Nagata, Yoshitaka Naito, Shinsuke Isobe, Takamasa Iwakura, Tomoyuki Fujikura, Naro Ohashi, Akihiko Kato, Hideo Yasuda  
*First Department of Medicine, Hamamatsu University School of Medicine, Japan*

**O-6 Leukotriene B<sub>4</sub>-BLT1-dependent neutrophil recruitment contributes to the pathogenesis of crescent glomerulonephritis**

Ryotaro Shioda<sup>1,2</sup>, Airi Jo-Watanabe<sup>2,3</sup>, Toshiaki Okuno<sup>2</sup>, Kazuko Saeki<sup>2</sup>, Maiko Nakayama<sup>1</sup>, Takehiko Yokomizo<sup>2</sup>, Yusuke Suzuki<sup>1</sup>

<sup>1</sup>*Department of Nephrology, Juntendo University Faculty of Medicine, Japan,*

<sup>2</sup>*Department of Biochemistry, Juntendo University Graduate School of Medicine, Japan,*

<sup>3</sup>*AMED-PRIME, Japan Agency for Medical Research and Development, Japan*

**O-7 Hepatic phosphate uptake and hepatic afferent nerve transmission play pivotal roles in the maintenance of serum phosphate levels in a FGF23, PTH, and vitamin D independent manner**

Seiichi Yasuda, Kazunori Inoue, Atsuhiko Imai, Hiroki Okushima, Yusuke Katsuma, Ayumi Matsumoto, Isao Matsui, Yoshitaka Isaka  
*Department of Nephrology, Osaka University Graduate School of Medicine, Japan*

**O-8 Dietary magnesium insufficiency induces salt-sensitive hypertension in mice associated with reduced kidney COMT activity**

Asako Kumagai<sup>1</sup>, Keizo Kanasaki<sup>2</sup>

<sup>1</sup>*Department of Obstetrics and Gynecology, Juntendo University, Japan,*

<sup>2</sup>*Department of Internal Medicine I, Faculty of Medicine, Shimane University, Japan*

**15:25–15:55 Sponsored Seminar 2**

Sponsored by Sumitomo Dainippon Pharma Co.,Ltd.

Chair : Takashi Wada (*Department of Nephrology and Laboratory Medicine, Kanazawa University, Japan*)

**SS-2 Management of type 2 diabetes in diabetic kidney disease**

Akira Mima

*Department of Nephrology, Osaka Medical and Pharmaceutical University, Japan*

**16:05–17:05 Oral Presentations**

**“Clinical”**

Chairs : Kunihiko Yamagata (*Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan*)

Hitoshi Sugiyama (*Okayama University Hospital, Japan*)

**O-9 High chronicity index of the revised International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification of lupus nephritis is associated with increased risk of end-stage kidney disease: a retrospective single-center study**

Shiori Nakagawa<sup>1</sup>, Tadashi Toyama<sup>1,2</sup>, Yasunori Iwata<sup>1</sup>, Megumi Oshima<sup>1</sup>, Hisayuki Ogura<sup>1</sup>, Koichi Sato<sup>1</sup>, Yuta Yamamura<sup>1</sup>, Taro Miyagawa<sup>1</sup>, Shinji Kitajima<sup>1</sup>, Akinori Hara<sup>1,3</sup>, Norihiko Sakai<sup>1</sup>, Miho Shimizu<sup>1</sup>, Takashi Wada<sup>1</sup>

<sup>1</sup>*Department of Nephrology and Laboratory Medicine, Kanazawa University, Japan,*

<sup>2</sup>*Innovative Clinical Research Center, Kanazawa University Hospital, Japan,*

<sup>3</sup>*Department of Public Health, Kanazawa University, Japan*

**O-10 Increasing gender difference in the incidence of end-stage of renal disease in Okinawa**

Chisato Fukuhara<sup>1</sup>, Kentaro Kohagura<sup>2</sup>, Iseki Kunitoshi<sup>3</sup>

<sup>1</sup>*Department of Nephrology, Heartlife hospital, Japan,*

<sup>2</sup>*Dialysis Unit, University Hospital of the Ryukyus, Japan,*

<sup>3</sup>*Okinawa Heart and Renal Association, Japan*

**O-11 Long-term care needs and incidence of end-stage kidney disease: a retrospective cohort study**

Ryuichi Yoshimura<sup>1</sup>, Ryohei Yamamoto<sup>1</sup>, Maki Shinzawa<sup>2</sup>, Rie Kataoka<sup>3</sup>, Nami Ikeguchi<sup>3</sup>, Suzuna Kanda<sup>3</sup>, Yuki Nii<sup>3</sup>, Hiroshi Toki<sup>1</sup>, Toshiki Moriyama<sup>1</sup>

<sup>1</sup>*Health and Counseling Center, Osaka University, Japan,*

<sup>2</sup>*Department of Nephrology, Osaka University Graduate School of Medicine, Japan,*

<sup>3</sup>*Health Promotion Division, Neyagawa City Public Health Center, Japan*

**O-12 Urinary phenyl sulfate predict the 2-year ACR deterioration in a DKD cohort**

Koichi Kikuchi<sup>1</sup>, Ryota Kujirai<sup>3</sup>, Yotaro Matsumoto<sup>3</sup>, Koki Mise<sup>4</sup>, Tomohiro Nakamura<sup>2</sup>, Jun Wada<sup>4</sup>, Yoshihisa Tomioka<sup>3</sup>, Takaaki Abe<sup>1,5</sup>

<sup>1</sup>*Tohoku University Hospital, Japan,*

<sup>2</sup>*Tohoku Medical Megabank Organization, Tohoku University, Japan,*

<sup>3</sup>*Tohoku University Graduate School of Pharmaceutical Sciences, Japan,*

<sup>4</sup>*Okayama University, Japan,*

<sup>5</sup>*Tohoku University Graduate School of Biomedical Engineering, Japan*

**O-13 Performance of new CKD EPI equation without race among Japanese patients**

Yoshinari Yasuda<sup>1,2</sup>, Masaru Horio<sup>1</sup>, Enyu Imai<sup>1</sup>, Tsuyoshi Watanabe<sup>1</sup>,  
Akira Hishida<sup>1</sup>, Shoichi Maruyama<sup>2</sup>, Seiichi Matsuo<sup>1</sup>

<sup>1</sup>Study Group of developing the Japanese equation for estimated GFR, Japan.

<sup>2</sup>Department of Nephrology, Nagoya University Graduate School of Medicine, Japan

**17:05-17:45 Sponsored Seminar 3**

Sponsored by Ono Pharmaceutical Co., Ltd. / AstraZeneca K.K.

Chair : Naoki Kashihara (*Division of Nephrology and Hypertension, Kawasaki Medical School, Japan*)

**SS-3 SGLT2 inhibitor as a promising therapeutic strategy for chronic kidney disease**

Kei Fukami

*Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Japan*

**17:55-18:40 Controversy in the Treatment of Glomerulonephritis**

Chair : Masaomi Nangaku (*Division of Nephrology and Endocrinology, the University of Tokyo Graduate School of Medicine, Japan*)

Yon Su Kim (*Seoul National University College of Medicine, Republic of Korea*)

**Panelists** Li Zuo

*Peking University First Hospital, China*

Kearkiat Praditpornsilpa

*Chulalongkorn University, Thailand*

Chi-Chih Hung

*Kaohsiung Medical University, Taiwan*

**18:40-19:25 Invited Lecture**

Chair : Shoichi Maruyama (*Department of Nephrology, Internal Medicine, Nagoya University Graduate School of Medicine, Japan*)

**IL-1 Treatment of ANCA-Associated Vasculitis**

David Jayne

*University of Cambridge, UK*

**19:25- Closing Remarks**